Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business TAIPEI, TAIWAN, October 3, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today announced the appointment of J.D. Mowery to the newly created position of Division President of Bora’s CDMO business. “Through our acquisitions and joint...
Taipei, Taiwan - September 4, 2024 - Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the biosimilar-focused biopharmaceutical company and CDMO, today announced that its Board of Directors has appointed Stephen Lam as the Company's Chief Executive Officer, effective September 5, 2024. Stephen succeeds Henry Chen, who shall remain the Chairman until the closing of Tanvex’s...
Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved a strategic investment into Tanvex Biopharma Co., Ltd. ("Tanvex", TWSE: 6541), whereby Bora Biologics, a wholly owned subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities...
TAIPEI, TAIWAN, August 20th 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a a global leader in pharmaceutical manufacturing, today announced that it has completed the acquisition from Emergent BioSolutions (“Emergent”, NYSE: EBS) of its sterile manufacturing facility in Baltimore-Camden, Maryland. The facility adds drug product fill/finish to Bora’s extensive...